Core Viewpoint - The recent comments by former President Trump regarding the price reduction of the obesity drug Ozempic have significantly impacted the stock prices of major players in the weight loss drug market, specifically Novo Nordisk and Eli Lilly, leading to a decline in investor enthusiasm for obesity treatment drugs [2][4]. Group 1: Stock Market Impact - On October 17, 2023, shares of Novo Nordisk and Eli Lilly fell by 3.07% and 2.02% respectively, following Trump's announcement that the price of Ozempic would soon be drastically reduced to $150 per month for consumers [3][4]. - Novo Nordisk's stock has seen a cumulative decline of approximately 58% over the past 12 months due to market concerns about the competitiveness of Ozempic [4]. Group 2: Pricing Strategies and Government Actions - The Trump administration is negotiating with pharmaceutical companies to lower drug prices, extending strategies previously applied to fertility treatment drugs to the weight loss drug sector [2][8]. - The actual net price of Ozempic is estimated to be 60% to 70% lower than its listed price of $1,000, due to rebates from insurance companies [4]. Group 3: Future Market Dynamics - Analysts predict that the introduction of oral weight loss drugs by Novo Nordisk and Eli Lilly by 2026 will likely see pricing comparable to existing injectable drugs, reflecting a shift in pricing strategy under government pressure [8][9]. - The global market for oral GLP-1 drugs is expected to reach a 15% share by 2030, with a potential market size of $150 billion [9].